In vitro incorporation studies of Tc-99m-alendronate sodium at different bone cell lines

Basit Öğe Kaydı
dc.contributor.authorGundogdu, Evren
dc.contributor.authorIlem-Ozdemir, Derya
dc.contributor.authorAsikoglu, Makbule
dc.date.accessioned2019-10-27T22:05:17Z
dc.date.available2019-10-27T22:05:17Z
dc.date.issued2014
dc.departmentEge Üniversitesien_US
dc.description.abstractBisphosphonates can be labeled with Technetium-99m (Tc-99m) and are used for bone imaging because of their good localization in the skeleton and rapid clearance from soft tissues. Over the last decades bone scintigraphy has been used extensively in the evaluation of oncological patients to provide information about the sites of bone lesions, their prognosis and the effectiveness of therapy by showing the sequential changes in tracer uptake. Since the lesion visualization and lesion/bone ratio are important utilities for a bone scanning radiopharmaceutic; in this study incorporation of Tc-99m labeled alendronate sodium (Tc-99m-ALD) was evaluated in U2OS (human bone osteosarcoma) and NCI-H209 (human bone carcinoma) cell lines. ALD was directly labeled by Tc-99m, radiochemical purity and stability of the complex were analyzed by radioactive thin layer chromatography and radioactive high performance liquid chromatography studies. For cell incorporation study, NCI-H209 and U2OS cell lines were used with standard cell culture methods. The six well plates were used for all experiments and the integrity of each cell monolayer was checked by measuring its transepithelial electrical resistance (TEER) with an epithelial voltammeter. Results confirmed that ALD was successfully radiolabeled with Tc-99m. Tc-99m-ALD incorporated with NCI-H209 and U2OS cells. The uptake percentages of Tc-99m-ALD in NCI-H209 and U2OS cell lines were found significantly different. Since Tc-99m-ALD highly uptake in cancer cell line, the results demonstrated that radiolabeled ALD may be a promising agent for bone cancer diagnosis.en_US
dc.description.sponsorshipEge University Nuclear Medicine DepartmentEge Universityen_US
dc.description.sponsorshipThe authors would like to acknowledge the support of Ege University Nuclear Medicine Department to obtain the <SUP>99m</SUP>Tc radionuclide.en_US
dc.identifier.doi10.1007/s10967-013-2833-z
dc.identifier.endpage1260en_US
dc.identifier.issn0236-5731
dc.identifier.issn1588-2780
dc.identifier.issn0236-5731en_US
dc.identifier.issn1588-2780en_US
dc.identifier.issue3en_US
dc.identifier.startpage1255en_US
dc.identifier.urihttps://doi.org/10.1007/s10967-013-2833-z
dc.identifier.urihttps://hdl.handle.net/11454/48317
dc.identifier.volume299en_US
dc.identifier.wosWOS:000332034400014en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal of Radioanalytical and Nuclear Chemistryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBone scintigraphyen_US
dc.subjectBone cancer diagnosisen_US
dc.subjectTc-99m-alendronate sodiumen_US
dc.subjectCell incorporation studyen_US
dc.subjectHuman bone carcinomaen_US
dc.subjectHuman bone osteosarcomaen_US
dc.titleIn vitro incorporation studies of Tc-99m-alendronate sodium at different bone cell linesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu